Supplementary Tables 1 and 2. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.

  • John F. De Groot (Contributor)
  • Martina Ott (Creator)
  • Jun Wei (Creator)
  • Cynthia Kassab (Creator)
  • Dexing Fang (Creator)
  • Hinda Najem (Creator)
  • Barbara J. O’Brien (Contributor)
  • Shiao Pei Weathers (Creator)
  • Nazanin Majd (Creator)
  • Rebecca Harrison (Creator)
  • Gregory N. Fuller (Contributor)
  • Jason T. Huse (Creator)
  • James Long (Creator)
  • Ray Sawaya (Creator)
  • Ganesh Rao (Creator)
  • Tobey J. MacDonald (Contributor)
  • Waldemar Priebe (Creator)
  • Michael George DeCuypere (Contributor)
  • Amy B Heimberger (Creator)

Dataset

Description

Supplementary Table 1. Supplementary Table 2: PK Modeling Summary of WP1066 in Human Plasma
Date made available2022
PublisherFuture Science Group

Access Dataset

Cite this